SUBSCRIBE
SUBSCRIBE
Patience Asanga

Patience Asanga

Freelance writer

Patience Asanga is a Nigeria-based science writer. She has a BSc in animal and environmental biology from the University of Benin, Nigeria. Patience enjoys writing about various topics across the life sciences, especially cell biology and immunology. She also covers the biopharmaceutical industry. Her work has appeared in Knowable Magazine, The Scientist, Scidev, BioSpace and Live Science.

illustration of hands reaching for a semaglutide injector over an image of the Earth
GLP-1
As Novo and Lilly Focus on a Few Big Markets, Sanofi Seeks Global Reach for Diabetes GLP-1 Drug
Experts say Novo Nordisk and Eli Lilly’s GLP-1 drugs are unlikely to reach more countries in the near term, but Sanofi’s diabetes treatment has gained ground globally.
August 21, 2024
 · 
5 min read
 · 
Patience Asanga
Illustration of pie chart composed of people
Drug Development
Patient Assistance Programs: A Source of Real-World Data?
Patient assistance programs may actually be a two-way street, providing patients with drugs and companies with data.
July 8, 2024
 · 
3 min read
 · 
Patience Asanga
Pictured: Collage of a brain and stem cells/Taylor
Drug Development
Early Data Indicate Cell Therapies Could ‘Reset the Clock’ in Parkinson’s
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
April 18, 2024
 · 
5 min read
 · 
Patience Asanga
Pictured: Vintage computer and wasted money
Drug Delivery
Poor Customer Data Management Costs Pharma Companies Money: Report
While some companies look to AI models to stop revenue leakage in business operations, experts say more fundamental issues must first be addressed.
April 1, 2024
 · 
5 min read
 · 
Patience Asanga
Pictured: Collage of biopharma production and Nige
Drug Delivery
GSK, Sanofi Exit Nigerian Market Amid Lingering Foreign Exchange Crisis
The biopharma industry in Nigeria takes a hit as GSK and Sanofi shut down their commercialization efforts in the country.
February 27, 2024
 · 
4 min read
 · 
Patience Asanga
Pictured: USA money squeeze with pharma components
Drug Development
High Costs of GLP-1 Drugs Fuel Debate
Stringent regulation, manufacturing costs and absence of price control contribute to high GLP-1 agonist costs in the U.S. Patients could go to other countries for cheaper treatment.
January 30, 2024
 · 
4 min read
 · 
Patience Asanga
Pictured: The earth as seen from space/iStock, dig
Policy
Global Regulators Increase CAR T Scrutiny in Wake of FDA’s Investigation
Regulatory authorities worldwide are tightening their monitoring mechanisms and launching their own investigations after reports of secondary malignancies potentially linked to chimeric antigen receptor T cell therapies.
January 18, 2024
 · 
5 min read
 · 
Patience Asanga
Pictured: Syringe and vial on background of market
13 Therapies Make Clarivate’s 2024 Drugs to Watch List
Clarivate’s latest Drug to Watch list highlights new modalities shaping drug development, including gene editing and artificial intelligence.
January 10, 2024
 · 
4 min read
 · 
Patience Asanga
Aerial view of Cape Town, South Africa/iStock, Ben
As Its Domestic Market Grows, South Africa Moves Toward Greater Local Biopharmaceutical Production
Partnerships with companies based in the U.S. and elsewhere are one factor driving growth in the industry, but obstacles remain.
December 13, 2023
 · 
5 min read
 · 
Patience Asanga
A doctor watches as a patient goes into a CT scann
Updated: Radiopharmaceuticals Market Predicted to Grow Rapidly Over Next Decade
Fueled partly by increasing lifespans and cancer incidence, the area’s worth is projected to soar to 13.67 billion by 2032, Precedence Research reports.
December 5, 2023
 · 
5 min read
 · 
Patience Asanga
Chart showing rapid growth/iStock, Geerati
Biologics Projected to Keep Gaining Ground in Cancer Therapeutics Market
The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.
November 20, 2023
 · 
4 min read
 · 
Patience Asanga